Marinus Pharmaceuticals/MRNS

$1.44

4.35%
-
1D1W1MYTD1YMAX

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Ticker

MRNS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Scott Braunstein

Employees

165

Headquarters

Radnor, United States

MRNS Metrics

BasicAdvanced
$75.8M
Market cap
-
P/E ratio
-$2.63
EPS
1.20
Beta
-
Dividend rate
$75.8M
1.19807
$11.26
$1.11
1.61M
4.068
4.008
366.376
435.276
-14.97%
-65.7%
-219.71%
-77.53%
2.446
4.493
4.522
21.63%
-537.2%
162.26%

What the Analysts think about MRNS

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
511.11% upside
High $27.00
Low $2.00
$1.44
Current price
$8.80
Average price target

MRNS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-587.32% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$7.1M
-2.74%
Net income
$-41.7M
26.75%
Profit margin
-587.32%
30.32%

MRNS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 18.8%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.67
-$0.61
-$0.61
-$0.74
-
Expected
-$0.72
-$0.72
-$0.66
-$0.62
-$0.66
Surprise
-7.31%
-14.89%
-7.66%
18.8%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Marinus Pharmaceuticals stock?

Marinus Pharmaceuticals (MRNS) has a market cap of $75.8M as of April 23, 2024.

What is the P/E ratio for Marinus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Marinus Pharmaceuticals (MRNS) stock is 0 as of April 23, 2024.

Does Marinus Pharmaceuticals stock pay dividends?

No, Marinus Pharmaceuticals (MRNS) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Marinus Pharmaceuticals dividend payment date?

Marinus Pharmaceuticals (MRNS) stock does not pay dividends to its shareholders.

What is the beta indicator for Marinus Pharmaceuticals?

Marinus Pharmaceuticals (MRNS) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Marinus Pharmaceuticals stock price target?

The target price for Marinus Pharmaceuticals (MRNS) stock is $8.8, which is 498.64% above the current price of $1.47. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Marinus Pharmaceuticals stock

Buy or sell Marinus Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing